CN104829532A - Method for preparing lorcaserin hydrochloride single crystal - Google Patents
Method for preparing lorcaserin hydrochloride single crystal Download PDFInfo
- Publication number
- CN104829532A CN104829532A CN201510250174.8A CN201510250174A CN104829532A CN 104829532 A CN104829532 A CN 104829532A CN 201510250174 A CN201510250174 A CN 201510250174A CN 104829532 A CN104829532 A CN 104829532A
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- green card
- card look
- woods hydrochloride
- look woods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种制备绿卡色林盐酸盐大颗粒单晶体的方法,其特征在于包括以下步骤:室温下以水、乙腈和乙醇混合溶剂为重结晶媒介,其中水,乙腈和乙醇三者质量比为1:(0.5~5):(0.5~1),将绿卡色林盐酸盐粗品溶解于混合溶剂中,将体系升温至40~60℃,待溶清后置于密闭容器中加压至2~5个大气压,降温到0~10℃静置重结晶1~3天,最后抽滤干燥得到尺寸大、晶形完整的大颗粒单晶体。本发明操作简便,适合工业化生产,环保,产物纯度高,收率高。
The invention relates to a method for preparing large single crystals of greencaserin hydrochloride, which is characterized in that it comprises the following steps: using a mixed solvent of water, acetonitrile and ethanol as the recrystallization medium at room temperature, wherein the mass ratio of water, acetonitrile and ethanol is 1: (0.5~5): (0.5~1), dissolve the crude greencaserin hydrochloride in a mixed solvent, raise the temperature of the system to 40~60°C, put it in a closed container and pressurize it to 2~5 atmospheres, lower the temperature to 0~10°C and let it stand for recrystallization for 1~3 days, and finally filter and dry to obtain large single crystals with large size and complete crystal form. The invention has the advantages of simple and convenient operation, suitability for industrial production, environmental protection, high product purity and high yield.
Description
技术领域 technical field
本发明属于原料药制备领域,具体是一种制备绿卡色林盐酸盐大颗粒单晶的方法。 The invention belongs to the field of preparation of crude drugs, in particular to a method for preparing large-particle single crystals of green caserin hydrochloride.
背景技术 Background technique
绿卡色林盐酸盐(Lorcaserin Hydrochloride)是一类R构型的环胺盐酸盐,其化学名称为(R)-氯-1-甲基-2,3,4,5-四氢-1H-3-苯并氮杂卓盐酸盐,分子式为C11H15Cl2N·0.5H2O结构如下: Lorcaserin Hydrochloride is a kind of R-configuration cyclic amine hydrochloride, its chemical name is (R)-chloro-1-methyl-2,3,4,5-tetrahydro-1H -3-Benzazepine hydrochloride, the molecular formula is C 11 H 15 Cl 2 N · 0.5H 2 O. The structure is as follows:
绿卡色林是作用于中枢神经系统抑制食欲的药物,于2005年由美国艾尼纳制药公司开发研制,其特异性靶点是5-HT2C,对于控制食欲有很强的作用,而对于5-HT2A或者5-HT2B受体则没有作用,这两个受体分别与心血管疾病和引起幻觉相关。最新的一项大型Ⅲ期临床试验结果显示,绿卡色林具有减肥作用,而且对心脏瓣膜和肺动脉没有任何影响。与别的减肥药不同,绿卡色林在减肥同时,还能改善心率压以及低密度脂蛋白胆固醇(LDL-C)水平。绿卡色林减肥的优势并不在疗效,而在于其安全性明显比现有药物好,此外对于2型糖尿病及有心血管风险因素人群也具有明确的益处,因此开发绿卡色林具有很好的市场前景。 Lvcaserin is a drug that acts on the central nervous system to suppress appetite. It was developed by the American Enina Pharmaceutical Company in 2005. Its specific target is 5-HT 2C , which has a strong effect on appetite control. There was no role for -HT 2A or 5-HT 2B receptors, which are associated with cardiovascular disease and hallucinations, respectively. The latest results of a large-scale phase III clinical trial showed that greencaserin has a weight-loss effect and has no effect on heart valves and pulmonary arteries. Different from other weight-loss drugs, Greencaserin can also improve heart rate, blood pressure and low-density lipoprotein cholesterol (LDL-C) levels while losing weight. The advantage of lvcaserin for weight loss is not in its efficacy, but in its safety, which is significantly better than existing drugs. In addition, it also has clear benefits for people with type 2 diabetes and cardiovascular risk factors. Therefore, the development of lvcaserin has a good market prospect .
目前在美国销售的绿卡色林药品名为Belviq,美国专利US8168624B2公开了绿卡色林三种晶型,晶型Ⅰ、晶型Ⅱ以及晶型Ⅲ。本发明基于稳定的晶型Ⅲ制备了其大颗粒单晶体。药物产品的晶型会极大地影响药物的溶出速率和生物利用度,另外根据制剂的要求,原料药颗粒度在合理的范围内易于制剂。因而,如何采用简单、可靠、收率高的方法对绿卡色林盐酸盐晶体再次提取,制得纯度高的单晶体,以达到最佳的药物疗效是亟待解决的问题。 The green caserin drug currently sold in the United States is called Belviq. US Patent US8168624B2 discloses three crystal forms of green caserin, crystal form I, crystal form II and crystal form III. The present invention prepares its large grain single crystal based on the stable crystal form III. The crystal form of the drug product will greatly affect the dissolution rate and bioavailability of the drug. In addition, according to the requirements of the preparation, the particle size of the raw material drug is easy to prepare within a reasonable range. Therefore, how to adopt a simple, reliable, and high-yield method to re-extract chlorocaserin hydrochloride crystals to obtain single crystals with high purity so as to achieve the best drug efficacy is an urgent problem to be solved.
发明内容 Contents of the invention
本发明提供了一种操作简便,适合工业化生产,且制得的晶体颗粒大、结构完整,利于制剂的绿卡色林盐酸盐单晶体新方法。 The invention provides a new method for greencaserin hydrochloride single crystal which is easy to operate, suitable for industrial production, and has large crystal particles and complete structure, which is convenient for preparation.
本发明的目的是通过如下技术方案实现的: The purpose of the present invention is achieved through the following technical solutions:
本发明提供的制备绿卡色林盐酸盐大颗粒单晶体的方法,是通过对多种溶剂和重结晶条件的选择,最终确定以水、乙腈和乙醇等为溶剂重结晶得到绿卡色林盐酸盐大颗粒单晶体,具体步骤如下: The method for preparing large-particle single crystals of greencaserin hydrochloride provided by the present invention is to finally obtain greencaserin hydrochloride by recrystallizing with water, acetonitrile and ethanol as solvents through the selection of various solvents and recrystallization conditions. Large-grain single crystal, the specific steps are as follows:
1)在40~60℃温度条件下,将绿卡色林盐酸盐粗品按一定配比溶解于水、乙腈和乙醇的混合溶剂中,搅拌均匀至澄清。 1) Dissolve the crude greencaserin hydrochloride in a mixed solvent of water, acetonitrile and ethanol according to a certain ratio at a temperature of 40~60°C, and stir evenly until clarification.
2)将得到的溶清液置于密闭容器中加压至2~5个大气压,降温至0~10℃静置重结晶1~3天,待溶液中析出大颗粒晶体,抽滤; 2) Put the obtained solution in a closed container and pressurize it to 2~5 atmospheres, cool down to 0~10°C and let it stand for recrystallization for 1~3 days. After the large crystals are precipitated in the solution, filter it with suction;
3)将步骤2)得到的晶体在50~80℃真空干燥2~5小时,得到绿卡色林盐酸盐大颗粒单晶体。 3) The crystals obtained in step 2) were vacuum-dried at 50-80°C for 2-5 hours to obtain large single crystals of greencaserin hydrochloride.
上述方法制得的绿卡色林盐酸盐为无色透明的大颗粒单晶体,对其进行了差示扫描量热、扫描电镜、偏光显微镜和单晶X射线衍射分析。绿卡色林盐酸盐的大颗粒单晶体属于正交晶系,空间群为:P212121,晶胞参数为a=8.2396(4)Å;b=11.5169(7)Å;c=26.5462(13)Å;α=90°;β=90°;γ=90°,Z=4,晶胞体积达2519.1(2)Å3。 The green caserin hydrochloride prepared by the above method is a colorless and transparent large particle single crystal, which has been analyzed by differential scanning calorimetry, scanning electron microscope, polarizing microscope and single crystal X-ray diffraction. The large single crystal of green caserin hydrochloride belongs to the orthorhombic crystal system, the space group is: P2 1 2 1 2 1 , and the unit cell parameters are a=8.2396(4)Å; b=11.5169(7)Å; c=26.5462 (13)Å; α=90°; β=90°; γ=90°, Z=4, and the unit cell volume is 2519.1(2)Å 3 .
本发明提供的制备绿卡色林盐酸盐大颗粒单晶的方法的优点在于: The advantage of the method for preparing the large particle single crystal of greencaserin hydrochloride provided by the invention is:
1)操作简单,成本低廉,收率高达85%以上; 1) The operation is simple, the cost is low, and the yield is as high as 85% or more;
2)得到的单晶体纯度高、晶形完整,颗粒大便于制剂。 2) The obtained single crystal has high purity, complete crystal form, and large particles, which are convenient for preparation.
附表说明Schedule Notes
图1为本发明的实施例1制备的绿卡色林盐酸盐大颗粒单晶体的差示扫描的谱图; Fig. 1 is the spectrogram of the differential scanning of the large particle single crystal of green caserin hydrochloride prepared by embodiment 1 of the present invention;
图2为本发明的实施例6制备的绿卡色林盐酸盐大颗粒单晶体的偏光显微镜的谱图; Fig. 2 is the spectrogram of the polarizing microscope of the large particle single crystal of green caserin hydrochloride prepared by embodiment 6 of the present invention;
图3为本发明的实施例6制备的绿卡色林盐酸盐大颗粒单晶体的晶体结构图。 Fig. 3 is the crystal structure diagram of the large particle single crystal of green caserin hydrochloride prepared in Example 6 of the present invention.
图4为本发明的实施例7制备的绿卡色林盐酸盐多晶粉末的X射线衍射谱图。 Fig. 4 is the X-ray diffraction spectrum of the green caserin hydrochloride polycrystalline powder prepared in Example 7 of the present invention.
具体实施方式 Detailed ways
实施例1 Example 1
称取1g绿卡色林盐酸盐样品,室温下加入3g水+8g乙腈混合溶剂,将体系升温至50℃,搅拌均匀,待溶清后抽滤除去杂质,置于密闭容器中加压至2个大气压,降温至10℃静置重结晶3天,得到500-800微米尺寸的大颗粒单晶体。抽滤后,置于真空干燥箱中干燥5小时,称重后计算收率为86%。取样进行热分析测试,得其熔点为200±1℃,焓值为67.62J/g,如图1所示其热分析曲线。 Weigh 1g of greencaserin hydrochloride sample, add 3g of water + 8g of acetonitrile mixed solvent at room temperature, raise the temperature of the system to 50°C, stir evenly, remove impurities by suction filtration after dissolution, and place in a closed container to pressurize to 2 Atmospheric pressure, lower the temperature to 10°C and stand for recrystallization for 3 days to obtain large single crystals with a size of 500-800 microns. After suction filtration, it was dried in a vacuum oven for 5 hours, and the calculated yield was 86% after weighing. Samples were taken for thermal analysis testing, and its melting point was 200±1°C, and its enthalpy value was 67.62 J/g. The thermal analysis curve is shown in Figure 1.
实施例2 Example 2
称取1g绿卡色林盐酸盐样品,室温下加入3g水+2.5g甲醇混合溶剂,将体系升温至50℃,搅拌均匀,待溶清后,抽滤除去杂质后置于密闭容器中加压至2个大气压,降温至10℃静置重结晶3天,得到大于500-700微米尺寸的大颗粒单晶体 。抽滤后,置于真空干燥箱中干燥5小时,称重后计算收率为88%。 Weigh 1g of green caserin hydrochloride sample, add 3g of water + 2.5g of methanol mixed solvent at room temperature, raise the temperature of the system to 50°C, stir evenly, after the solution is clear, remove the impurities by suction filtration, place in a closed container and pressurize to 2 atmospheres, lower the temperature to 10°C and stand for recrystallization for 3 days to obtain large single crystals larger than 500-700 microns in size. After suction filtration, it was dried in a vacuum oven for 5 hours, and the calculated yield was 88% after weighing.
实施例3 Example 3
称取1g绿卡色林盐酸盐样品,室温下加入8g乙腈+2.5g甲醇混合溶剂,将体系升温至50℃,搅拌均匀,待溶清后,抽滤除去杂质后置于密闭容器中加压至2个大气压,降温至10℃静置重结晶3天,得到大于300-600微米尺寸的大颗粒单晶体。抽滤后,置于真空干燥箱中干燥5小时,称重后计算收率为87%。 Weigh 1g of greencaserin hydrochloride sample, add 8g of acetonitrile + 2.5g of methanol mixed solvent at room temperature, raise the temperature of the system to 50°C, stir evenly, after the solution is clear, remove the impurities by suction filtration, place in a closed container and pressurize to 2 atmospheres, lower the temperature to 10°C and stand for recrystallization for 3 days to obtain large single crystals with a size of 300-600 microns. After suction filtration, it was dried in a vacuum oven for 5 hours, and the calculated yield was 87% after weighing.
实施例4 Example 4
称取1g绿卡色林盐酸盐样品,室温下加入3g水+8g乙腈+2.5g甲醇混合溶剂,将体系升温至50℃,搅拌均匀,待溶清后,抽滤除去杂质后置于密闭容器中加压至2个大气压,降温至10℃静置重结晶3天,得到大于400-800微米尺寸的大颗粒单晶体。抽滤后,置于真空干燥箱中干燥5小时,称重后计算收率为91%。 Weigh 1g of green caserin hydrochloride sample, add 3g of water + 8g of acetonitrile + 2.5g of methanol mixed solvent at room temperature, raise the temperature of the system to 50°C, stir evenly, after the solution is clear, remove impurities by suction filtration and place in a closed container Pressurize to 2 atmospheres, cool down to 10°C and stand for recrystallization for 3 days to obtain large single crystals larger than 400-800 microns in size. After suction filtration, it was dried in a vacuum oven for 5 hours, and the calculated yield was 91% after weighing.
实施例5 Example 5
称取1g绿卡色林盐酸盐样品,室温下加入2g水+8g乙腈+1g甲醇混合溶剂中,将体系升温至50℃,搅拌均匀,待溶清后,抽滤除去杂质后置于密闭容器中加压至2个大气压,降温至10℃静置重结晶3天,得到大于500-800微米尺寸的大颗粒单晶体。抽滤后,置于真空干燥箱中干燥5小时,称重后计算收率为86%。 Weigh 1g of greencaserin hydrochloride sample, add 2g of water + 8g of acetonitrile + 1g of methanol mixed solvent at room temperature, raise the temperature of the system to 50°C, stir evenly, after it dissolves, filter it to remove impurities and place it in an airtight container Pressurize to 2 atmospheres, cool down to 10°C and stand for recrystallization for 3 days to obtain large single crystals larger than 500-800 microns in size. After suction filtration, it was dried in a vacuum oven for 5 hours, and the calculated yield was 86% after weighing.
实施例6 Example 6
称取1g绿卡色林盐酸盐样品,室温下加入3g水+6g乙腈+1g甲醇混合溶剂中,将体系升温至50℃,搅拌均匀,抽滤除去杂质后置于密闭容器中加压至2个大气压,降温至10℃静置重结晶3天,得到大量500-1000微米尺寸的大颗粒单晶体。抽滤后,置于真空干燥箱中干燥5小时,称重后计算收率为93%。通过偏光显微镜观察择取一颗尺寸为0.75mm ×0.85mm ×1.1mm的单晶颗粒在X射线衍射仪上进行测试分析,如图2所示偏光显微镜照片。结果显示,晶体属于正交晶系,空间群为:P2(1)P2(1)P(1),晶胞参数为a=8.2396(4)Å;b=11.5169(7)Å;c=26.5462(13)Å;α=90°;β=90°;γ=90°;Z=4。其晶体结构示意图如图3所示。 Weigh 1g of green caserin hydrochloride sample, add 3g of water + 6g of acetonitrile + 1g of methanol mixed solvent at room temperature, raise the temperature of the system to 50°C, stir evenly, remove impurities by suction filtration, place in a closed container and pressurize to 2 Atmospheric pressure, the temperature was lowered to 10°C and left to stand for recrystallization for 3 days, and a large number of large single crystals with a size of 500-1000 microns were obtained. After suction filtration, it was dried in a vacuum oven for 5 hours, and the calculated yield was 93% after weighing. A single crystal particle with a size of 0.75 mm × 0.85 mm × 1.1 mm was selected through polarizing microscope observation for testing and analysis on an X-ray diffractometer, as shown in the polarizing microscope photo in FIG. 2 . The results show that the crystal belongs to the orthorhombic crystal system, the space group is: P2(1)P2(1)P(1), and the unit cell parameters are a=8.2396(4)Å; b=11.5169(7)Å; c=26.5462 (13) Å; α=90°; β=90°; γ=90°; Z=4. The schematic diagram of its crystal structure is shown in Fig. 3 .
实施例7 Example 7
称取2g绿卡色林盐酸盐样品,室温下加入3g水+6g乙腈+1g甲醇混合溶剂中,将体系升温至50℃,搅拌均匀直接降温至10℃静置重结晶3天,得到大量小于200微米尺寸的粉末晶体。抽滤后,置于真空干燥箱中干燥5小时,称重后计算收率为73%。经多晶X射线衍射分析是晶型Ⅲ的多晶形式,如图4所示。 Weigh 2g of greencaserin hydrochloride sample, add 3g of water + 6g of acetonitrile + 1g of methanol mixed solvent at room temperature, raise the temperature of the system to 50°C, stir evenly and directly cool down to 10°C for 3 days to stand for recrystallization, and a large amount of less than 200 micron size powder crystals. After suction filtration, it was dried in a vacuum oven for 5 hours, and the calculated yield was 73% after weighing. According to polycrystalline X-ray diffraction analysis, it is a polycrystalline form of Form III, as shown in FIG. 4 .
本发明制得的绿卡色林盐酸盐晶型Ⅲ单晶体经研磨后得到多晶粉末,经粉末X射线衍射仪测试,在布拉格2θ角为3-40°(Cukα,λ=1.5418Å)时的粉末衍射图如图4所示,其特征谱线数据列在表1中。 在表1中d是晶格间距,I/I。代表相对强度,以最强谱线的百分比表示。结果显示由本发明得到的单晶体经研磨成多晶粉末后其晶型与文献报道的晶型Ⅲ一致。 The chlorocaserin hydrochloride crystal form III single crystal prepared by the present invention is ground to obtain a polycrystalline powder, which is tested by a powder X-ray diffractometer when the Bragg 2θ angle is 3-40° (Cukα, λ=1.5418Å). The powder diffraction pattern is shown in Figure 4, and its characteristic spectral line data are listed in Table 1. In Table 1 d is the lattice spacing, I/I. Represents the relative intensity, expressed as a percentage of the strongest spectral line. The results show that the crystal form of the single crystal obtained by the present invention is consistent with the crystal form III reported in the literature after being ground into polycrystalline powder.
表1 图4的特征谱线 Table 1 Characteristic lines of Figure 4
本发明制得的绿卡色林盐酸盐单晶体,借助单晶衍射仪可以得到详细的晶体学数据,其晶胞参数、晶系和空间群等信息,列于表2中。 For the greencaserin hydrochloride single crystal obtained in the present invention, detailed crystallographic data can be obtained by means of a single crystal diffractometer, and its unit cell parameters, crystal system and space group and other information are listed in Table 2.
表2 晶型Ⅲ的晶体学数据和其他结构确定 Table 2 Crystallographic data and other structural determinations of Form Ⅲ
通过单晶结构解析计算,该单晶的原子坐标列于表3中,键合长度列于表4中,键角列于表5中。 The atomic coordinates of the single crystal are listed in Table 3, the bond lengths are listed in Table 4, and the bond angles are listed in Table 5 through analysis and calculation of the single crystal structure.
表3 晶型Ⅲ的原子位置参数 Table 3 Atomic position parameters of crystal form Ⅲ
表4 晶型Ⅲ单晶体中分子内距离 Table 4 Intramolecular distances in Form Ⅲ single crystals
表5 晶型Ⅲ单晶体内非氢原子在分子内键合角度 Table 5 Intramolecular bonding angles of non-hydrogen atoms in crystal form Ⅲ
*角度以度为单位。最后小数位估算的标准偏差表示在括号内。 *Angles are in degrees. Estimated standard deviations to the last decimal place are indicated in parentheses.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510250174.8A CN104829532A (en) | 2015-05-15 | 2015-05-15 | Method for preparing lorcaserin hydrochloride single crystal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510250174.8A CN104829532A (en) | 2015-05-15 | 2015-05-15 | Method for preparing lorcaserin hydrochloride single crystal |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104829532A true CN104829532A (en) | 2015-08-12 |
Family
ID=53807776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510250174.8A Pending CN104829532A (en) | 2015-05-15 | 2015-05-15 | Method for preparing lorcaserin hydrochloride single crystal |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104829532A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084193A (en) * | 2004-12-21 | 2007-12-05 | 艾尼纳制药公司 | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
CN101466684A (en) * | 2006-04-03 | 2009-06-24 | 艾尼纳制药公司 | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
WO2011153206A1 (en) * | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
WO2014135545A1 (en) * | 2013-03-05 | 2014-09-12 | Sandoz Ag | Solid dispersion comprising amorphous lorcaserin hydrochloride |
-
2015
- 2015-05-15 CN CN201510250174.8A patent/CN104829532A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084193A (en) * | 2004-12-21 | 2007-12-05 | 艾尼纳制药公司 | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride |
CN101466684A (en) * | 2006-04-03 | 2009-06-24 | 艾尼纳制药公司 | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
WO2011153206A1 (en) * | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
WO2014135545A1 (en) * | 2013-03-05 | 2014-09-12 | Sandoz Ag | Solid dispersion comprising amorphous lorcaserin hydrochloride |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016184436A1 (en) | New crystal form of lenvatinib methanesulfonate salt and preparation method thereof | |
CN114605406B (en) | Crystal form of AMG510 compound and its preparation method and use | |
WO2017107972A1 (en) | Novel crystalline form of selective s1p1 receptor agonist and method for preparing same | |
WO2016150349A1 (en) | Preparation method of pci-32765 crystal form a | |
CN105622497A (en) | Isoliquiritigenin pyrazinamide eutectic crystal and preparation method thereof | |
CN105906558A (en) | Anti-fibrosis drug pirfenidone crystal forms and preparation method thereof | |
CN102643234B (en) | Edaravone polymorphic substance and preparation method thereof | |
CN102344478B (en) | Crystal of 17 alpha-acetoxyl group-11 beta-(4-N, N-dimethylamino phenyl)-19-norpregna-4, 9- diene-3, 20- ketone and preparation method thereof | |
CN103044364B (en) | Amorphous crystalline substance of a kind of Cabazitaxel and preparation method thereof | |
CN104829532A (en) | Method for preparing lorcaserin hydrochloride single crystal | |
CN108570045B (en) | Crystal form of anisodamine hydrobromide, preparation method and pharmaceutical composition thereof | |
CN102260281A (en) | Oxidized glaucine rare earth chelate compound as well as synthesis method and application thereof | |
CN111303099A (en) | Sphaelactone dimethylamine fumarate crystal form F and preparation method thereof | |
CN105753785B (en) | A kind of crystal formation of Edaravone and preparation method thereof | |
WO2018137670A1 (en) | Crystalline form of viral-protein inhibitor drug vx-287, and preparation method thereof and use thereof | |
WO2013075669A1 (en) | Crystal and amorphous substance of dapoxetine hydrochloride and preparation method therefor | |
CN103848879B (en) | A kind of with Isosorbide-5-Nitrae-Androstenedione for the method for Progesterone prepared by raw material | |
WO2017096690A1 (en) | Method for preparing amorphous form of darunavir | |
CN102321141B (en) | Amorphous substance of 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregn-4,9-diene-3,20-diketone and preparation method thereof | |
CN104876866A (en) | Alpha-crystal-form lappaconitine and preparation method thereof | |
WO2016150206A1 (en) | Dimethylamino glaucocalyxin a hydrochloride salt and crystalline form thereof | |
CN109651413B (en) | Rare earth complex with bromooxybicuculline as ligand and its synthesis method and application | |
CN111320601B (en) | Oroxylin crystal form and preparation method thereof | |
CN103408626B (en) | Halometasone polycrystalline type and preparation method thereof | |
WO2016157136A1 (en) | Crystalline forms of idelalisib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150812 |
|
RJ01 | Rejection of invention patent application after publication |